Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 86 Pages
|Evacetrapib(急性冠狀動脈症候群)- 預測與市場分析 Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 86 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
In addition to Merck's anacetrapib, Eli Lilly will be vying for space in the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly believes they have learned from the torcetrapib and dalcetrapib clinical trial failures. As with any aspirational LDL-C treatment, Eli Lilly had to demonstrate the LDL-C lowering capacity of evacetrapib.